

Clinical Microbiology Review

Richard Hankins, MD

Assistant Professor, UNMC Division of Infectious Diseases

Associate Medical Director, Infection Control & Epidemiology

Associate Medical Director, Antimicrobial Stewardship



Nebraska Infection
Control Network

1

Objectives

- Understand different types of culture media
- Identify common infectious organisms through microbiologic work up
- Review newer testing methodologies
- Understand antimicrobial resistance and the impact on infection control

2

Interpreting Microbiology Reports

- Types of Cultures
 - Blood
 - Sputum
 - Urine
 - Wound
 - Stool?
- When to order?
 - Actual suspicion of infection based on symptoms


Blood Cultures




3

How do we identify bacteria?

- Based on
 - Gram stain
 - Morphology
 - Growth characteristics
 - Biochemical tests
 - Growth requirements
 - Unique features
 - Smell (not anymore)




4



5

Gram + cocci in pairs and chains
(examples: *Streptococcus*, *Enterococcus*)



6

Patterns of Hemolysis

Alpha hemolytic

Example:
Streptococcus pneumoniae

Beta hemolytic

Example: Group A streptococcus
(*Streptococcus pyogenes*)




Gamma (no hemolysis):

Example: some
Enterococci

7


Gram + cocci in clusters (Example: *Staphylococcus*)



8


Staphylococcal testing

- Catalase test- bubbles result from breakdown of hydrogen peroxide
 - *Staphylococci* are catalase positive
- Coagulase test- converts fibrinogen to fibrin
 - *S. aureus* is coagulase +, other Staph species are coagulase negative



9

Gram Negative Identification



10


Gram Negative Identification: How do we know what is growing?

- Selective media- colony morphology
- Lactose fermentation test
- Oxidase test
- Many other biochemical tests




11

Lactose fermenting gram-negative rods




Examples: *E. coli*, *Klebsiella*, *Proteus*, *Enterobacter*



The term 'Enterobacterales' refers to the family of gram negative organisms that ferment lactose

12


Non-lactose fermenting gram-negative rod, oxidase positive



Examples: *Pseudomonas*, *Burkholderia*

13

Non-lactose fermenting gram-negative rod, oxidase negative



- Examples: *Acinetobacter*, *Stenotrophomonas*
- Tend to be multi-drug resistant

14

Special mention: *Clostridium difficile*

- Cultures for *C. difficile* are technically demanding, and are not widely available
- Testing algorithms can include:
 - Glutamate dehydrogenase (GDH) antigen assay (common to all strains of *C. difficile*)
 - Toxin A/B assay produced by some *C. difficile* strains
 - Nucleic acid amplification tests target toxin genes

Clostridium difficile Assay Results


GDH Result	Toxin Assay Result	Interpretation	Recommendations
Negative	Negative	No <i>C. difficile</i> present	No further action. Repeat testing is discouraged.
Positive	Positive	Toxigenic <i>C. difficile</i> is present	Utilize contact isolation precautions and begin therapy according to management algorithm. Repeat testing is discouraged.
Positive	Negative	Non-toxigenic <i>C. difficile</i> or false-negative toxin assay	DNA confirmatory test for toxin performed. Interpret based on this result
Negative	Positive	Indeterminate	Repeat test x 1.

Nebraska Medicine *C. difficile* test result interpretation

15

Acid fast bacilli

- Examples: *Mycobacterium tuberculosis*, other mycobacterial species




- **Mycobacterium Amplified Direct Test** – A PCR test is available in some laboratories for detection of *M. tuberculosis* complex from direct patient specimens.

16

Fungi


- Identification
 - KOH prep
 - Gram stain
 - India ink prep
 - Culture
 - Others (molecular methods)
- Yeasts grow quickly (3-5 days), but moulds and other fungi can take up to 4 weeks
- Candida- can be clinically important vs colonization
 - *Candida auris*- emerging global threat
- Environmental moulds (ex. Aspergillus)- may be significant infection control issues in construction, floods



17

Virology

- **Virus detection**
 - Culture
 - Direct viral antigen detection
 - Herpes Simplex Virus and Varicella Zoster Virus can be detected directly from skin lesions using a direct fluorescent antibody (DFA) test
 - Serology
 - Molecular methods (PCR)
 - Herpes viral panel
 - Respiratory viral panel





18

Non-culture Based Methods

- Next Generation Sequencing (NGS)

- Whole Genome Sequencing
- Metagenomic NGS
- Targeted NGS

- MALDI-TOF



19

Molecular Panels

- PCR based molecular panels
 - Respiratory PCR Panel
 - Meningitis PCR Panel
 - Serum Herpes Viral Panel
 - Gastrointestinal Pathogen Panel

20

General Principles of Antibiotic Resistance



21

Antibiotic Resistance

- Decreased ability of an antimicrobial agent to kill or inhibit the growth of a microbial organism
- Patient isolates are tested against antimicrobials in the microbiology laboratory
 - Automated liquid media microdilution systems
 - Disc diffusion
 - Etest




Etest



Disc Diffusion

22

Selection and Transmission of Antimicrobial Resistance



Frainow et al. Crit Care Clin 2011


23

Hospital Associated MRSA (HA-MRSA) vs. Community Associated MRSA (CA-MRSA)

- Strains of CA-MRSA were not derived from HA-MRSA
 - CA-MRSA likely originated from the transfer of the *mecA* gene to methicillin-sensitive *Staphylococcus aureus* (MSSA)
- The traditional epidemiologic definitions of HA-MRSA and CA-MRSA often no longer apply
 - Patients with infections due to CA-MRSA strains are frequently reported in the healthcare setting

24

The emergence of Methicillin-resistant *Staphylococcus aureus* (MRSA)



DeLeo et al. *J Clin Invest* 2009

25

Minimum Inhibitory Concentration (MIC)

- Measure of drug activity = minimum inhibitory concentration (MIC)
 - Breakpoints established by the U.S. Clinical and Laboratory Standards Institutes (CLSI)

Result	MIC	Clinical Correlation
Susceptible	≤ the defined susceptibility breakpoint	high likelihood of therapeutic success
Intermediate or Indeterminate	Intermediate value	therapeutic effect uncertain
Resistant	> the defined susceptibility breakpoint	high likelihood of therapeutic failure

26

Blood culture aerobic and anaerobic

Status: Final result Visible to patient: This result is not viewable by the patient. Next appt: None

Newer results are available. Click to view them now.

Source	2wk ago Blood, Peripheral Draw
Additional Information	None
Culture Result	Gram Stain result: Gram Positive Cocci in Clusters in Aerobic Bottle Only. Time to detection: 18.22 hours
	Methicillin Resistant Staphylococcus aureus (The Infectious Diseases Service may be consulted regarding treatment options for patients colonized or infected with methicillin-resistant Staphylococcus aureus.)
Micro Report Status	09/17/2014 Final
Organism	Methicillin Resistant Staphylococcus aureus
Resulting Agency	TNMC

Culture & Susceptibility

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS

Antibiotic	Sensitivity	MIC	Method	Status
Clindamycin	Resistant	>4	MIC	Final
Daptomycin	Susceptible	<=0.5	MIC	Final
Erythromycin	Resistant	>4	MIC	Final
Gentamicin	Susceptible	<=4	MIC	Final
Levofloxacin	Resistant	>4	MIC	Final
Linezolid	Susceptible	2	MIC	Final
Oxacillin	Resistant	>2	MIC	Final
Susceptibility to Oxacillin can be used to predict susceptibility to Cefazolin.				
Penicillin	Resistant	>8	MIC	Final
Rifampin	Susceptible	<=1	MIC	Final
Tetracycline	Resistant	>8	MIC	Final
Trimethoprim-Sulfa.	Susceptible	<=0.5/9.5	MIC	Final
Vancomycin	Susceptible	1	MIC	Final

Comments: METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS

Methicillin Resistant Staphylococcus aureus (The Infectious Diseases Service may be consulted regarding treatment options for patients colonized or infected with methicillin-resistant Staphylococcus aureus.)

27

MRSA Culture Result

3+ GROWTH STAPHYLOCOCCUS AUREUS
 OXACILLIN RESISTANCE INDICATES RESISTANCE TO ALL BETA
 LACTAMS, BETA LACTAM/BETA LACTAMASE INHIBITOR
 COMBINATIONS AND IMIPENEM. RIFAMPIN SHOULD NOT BE USED
 ALONE FOR TREATMENT OF BACTERIAL INFECTIONS AS
 RESISTANCE MAY DEVELOP RAPIDLY.

SUSCEPTIBILITY RESULTS:

S AUREUS	MIC	INTERP
CLINDAMYCIN	<=0.5	S
ERYTHROMYCIN	<=0.5	S
LINEZOLID	<=2	S
OXACILLIN	>=8	R
PENICILLIN	>=16	R
RIFAMPIN	<=1	S
TETRACYCLINE	<=1	S
TMP/SMX	<=10	S
VANCOMYCIN	2	S

****S. aureus with Penicillin resistance alone is not MRSA****

28

Multidrug-Resistant Gram-Negatives

- Multidrug-Resistant =
 - Typically resistant to at least one agent in 3 or more classes
- Extended Spectrum Beta-lactamase (ESBL)
 - Enzymes which degrade beta-lactam antibiotics
 - Particularly 3rd-generation cephalosporins like ceftriaxone, cefotaxime
 - ***E. coli*, *Klebsiella*, *Proteus*** well known to carry ESBL enzyme
 - Incidence increasing in US, even in outpatient settings


29

Carbapenem Resistance: Bad Bugs


- Carbapenem-resistant *Enterobacteriaceae* (CRE)
 - *E. coli*, *Klebsiella*, *Enterobacter*, *Citrobacter*, *Serratia*, etc.
 - Resistant to one of the carbapenems (meropenem, imipenem, ertapenem)
 - Documented production of a carbapenemase enzyme
- Carbapenemases
 - Hydrolyze all beta-lactams
 - Geographically localized in distribution
 - Many different types
 - *Klebsiella pneumoniae* carbapenemase (KPC)
 - New Delhi Metallo-beta-lactamase (NDM)

30

Patients with KPC-producing *Carbapenem-resistant Enterobacteriaceae* (CRE) reported to the Centers for Disease Control and Prevention (CDC) as of December 2017, by state




Patients with NDM-producing *Carbapenem-resistant Enterobacteriaceae* (CRE) reported to the Centers for Disease Control and Prevention (CDC) as of December 2017, by state



None
Reported

31

Candida auris



32

Thank you

- Tips:
 - Acute care: Make friends with your micro lab techs
 - Long term care/home health- identify points-of-contact if more information is needed
 - Communicate information on MDROs between facilities
 - If you are unsure of something: just ask!
 - State Health Dept, experienced IPs, Healthcare Epidemiologist, lab director are all resources
 - NICN, APIC, CDC, SHEA